These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6714285)

  • 1. Pharmacokinetics of nadolol in healthy subjects.
    Schäfer-Korting M; Bach N; Knauf H; Mutschler E
    Eur J Clin Pharmacol; 1984; 26(1):125-7. PubMed ID: 6714285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of nadolol elimination by activated charcoal and antibiotics.
    du Souich P; Caillé G; Larochelle P
    Clin Pharmacol Ther; 1983 May; 33(5):585-90. PubMed ID: 6839631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elimination of nadolol by patients with renal impairment.
    Herrera J; Vukovich RA; Griffith DL
    Br J Clin Pharmacol; 1979; 7 Suppl 2(Suppl 2):227S-231S. PubMed ID: 37878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacology and clinical pharmacokinetics of nadolol].
    Lazowski J; Wegrzyn B; Lypka A
    Pol Tyg Lek; 1981 Sep; 36(39):1521-4. PubMed ID: 6121320
    [No Abstract]   [Full Text] [Related]  

  • 5. Determination of orally coadministered nadolol and its deuterated analogue in human serum and urine by gas chromatography with selected-ion monitoring mass spectrometry.
    Cohen AI; Devlin RG; Ivashkiv E; Funke PT; McCormick T
    J Pharm Sci; 1984 Nov; 73(11):1571-5. PubMed ID: 6151597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of kinetic interactions of nadolol and propranolol with cimetidine.
    Duchin KL; Stern MA; Willard DA; McKinstry DN
    Am Heart J; 1984 Oct; 108(4 Pt 2):1084-6. PubMed ID: 6148867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic studies in patients with nadolol: oral and intravenous administration.
    Dreyfuss J; Brannick LJ; Vukovich RA; Shaw JM; Willard DA
    J Clin Pharmacol; 1977; 17(5-6):300-7. PubMed ID: 16040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of low-dose nadolol for ventricular arrhythmias.
    Morganroth J; Duchin KL
    Am J Cardiol; 1986 Aug; 58(3):273-8. PubMed ID: 3739916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nadolol in human serum and breast milk.
    Devlin RG; Duchin KL; Fleiss PM
    Br J Clin Pharmacol; 1981 Sep; 12(3):393-6. PubMed ID: 6117304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nadolol in hypertensive patients maintained on long-term hemodialysis.
    Michaels RS; Duchin KL; Akbar S; Meister J; Levin NW
    Am Heart J; 1984 Oct; 108(4 Pt 2):1091-4. PubMed ID: 6148869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic fate of carteolol hydrochloride, (OPC-1085) VIII, a new beta-adrenergic blocking agent. Pharmacokinetic studies of carteolol in man.
    Morita S; Iinuma M; Kido M; Sakuragi S; Kohri H; Nishino H
    Arzneimittelforschung; 1977; 27(12):2380-3. PubMed ID: 23800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative single dose and steady-state pharmacokinetics of bevantolol in young and elderly subjects.
    Selen A; Kinkel AW; Darke AC; Greene DS; Welling PG
    Eur J Clin Pharmacol; 1986; 30(6):699-704. PubMed ID: 2876899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, pharmacology of atenolol and effect of renal disease.
    Wan SH; Koda RT; Maronde RF
    Br J Clin Pharmacol; 1979 Jun; 7(6):569-74. PubMed ID: 465278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of oral timolol studied by mass fragmentography.
    Fourtillan JB; Courtois P; Lefebvre MA; Girault J
    Eur J Clin Pharmacol; 1981 Feb; 19(3):193-6. PubMed ID: 7215417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorodensitometric determination of nadolol in plasma and urine.
    Schäfer-Korting M; Mutschler E
    J Chromatogr; 1982 Jul; 230(2):461-5. PubMed ID: 7107792
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease.
    Kirch W; Rose I; Demers HG; Leopold G; Pabst J; Ohnhaus EE
    Clin Pharmacokinet; 1987 Aug; 13(2):110-7. PubMed ID: 2887325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Butofilolol pharmacokinetics in chronic renal insufficiency.
    Jeanniot JP; Houin G; Ledudal P; Cautreels W; Giudicelli CP; Tillement JP
    Int J Clin Pharmacol Res; 1984; 4(3):165-73. PubMed ID: 6149194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of adimolol after single and multiple dose administration in healthy volunteers.
    Wiedemann I; Peil H; Justus H; Adamus S; Brantl V; Lohmann H
    Arzneimittelforschung; 1985; 35(6):964-9. PubMed ID: 2862877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of the new antihypertensive agent nipradilol in rats. 2nd communication: A single oral administration of [14C]nipradilol to spontaneously hypertensive rats.
    Kimata H; Kabuto S; Yonemitsu M; Koide T; Nakao H; Suzuki J
    Arzneimittelforschung; 1985; 35(11):1680-4. PubMed ID: 4091870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atenolol, nadolol, and pindolol in angina pectoris on effort: effect of pharmacokinetics.
    Kostis JB; Lacy CR; Krieger SD; Cosgrove NM
    Am Heart J; 1984 Oct; 108(4 Pt 2):1131-6. PubMed ID: 6148873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.